← Back to Search

Behavioral Weight Loss for Psoriatic Arthritis and Obesity

Phase 1
Waitlist Available
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
new or previous diagnosis of symptomatic psoriatic arthritis
BMI ≥30kg/m2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post-intervention (i.e., immediately following the final bwlt session at 24-weeks)
Awards & highlights

Study Summary

This trial is testing the feasibility of a weight loss treatment program for people with psoriatic arthritis.

Eligible Conditions
  • Psoriatic Arthritis
  • Obesity

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have been diagnosed with psoriatic arthritis and it is causing symptoms.
Select...
You have a body mass index (BMI) of 30 or higher.
Select...
Willing to take part in a program called BWLT.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post-intervention (i.e., immediately following the final bwlt session at 24-weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and post-intervention (i.e., immediately following the final bwlt session at 24-weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intervention Acceptability
Intervention Feasibility (treatment adherence, Drop out/recruitment rates, protocol adherence)
Secondary outcome measures
Change in PsA symptom burden
Change in Weight

Trial Design

2Treatment groups
Experimental Treatment
Group I: Waitlist ControlExperimental Treatment1 Intervention
Participants in this arm will receive their treatment as usual for Psoriatic Arthritis and receive BWLT after the intervention group.
Group II: InterventionExperimental Treatment1 Intervention
16-week behavioural weight loss classes
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Waitlist Control for BWLT
2022
Completed Phase 1
~40
BWLT
2022
Completed Phase 1
~40

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
780 Previous Clinical Trials
841,696 Total Patients Enrolled
1 Trials studying Psoriatic Arthritis
528 Patients Enrolled for Psoriatic Arthritis

Media Library

BWLT Clinical Trial Eligibility Overview. Trial Name: NCT05225623 — Phase 1
Psoriatic Arthritis Research Study Groups: Waitlist Control, Intervention
Psoriatic Arthritis Clinical Trial 2023: BWLT Highlights & Side Effects. Trial Name: NCT05225623 — Phase 1
BWLT 2023 Treatment Timeline for Medical Study. Trial Name: NCT05225623 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current openings to participate in this clinical trial?

"According to the clinicaltrials.gov posting, this medical study is currently on the lookout for participants. The initial post was published February 1st 2022 and updated May 16th 2022."

Answered by AI

Has the Food and Drug Administration endorsed BWLT?

"Given the data available, BWLT's safety score was estimated to be a 1 since this is only a Phase 1 trial. Thus far, efficacy and safety have both been subject to minimal research."

Answered by AI

How many participants are being accepted into this clinical research endeavor?

"Affirmative. Clinicaltrials.gov displays that this investigation is at present searching for participants, which was initially announced on February 1st 2022 and last updated May 16th 2022. The trial requires 50 subjects to be enrolled across a single site."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What site did they apply to?
Behavioural Medicine Laboratory
What portion of applicants met pre-screening criteria?
Met criteria
~12 spots leftby Mar 2025